Nuvation Bio NUVB Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost
Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost at other companies
Other financials
Where this comes from
Reported directly by Nuvation Bio in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis.
The official record: Nuvation Bio’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nuvation Bio's debt securities, available-for-sale, maturity, allocated and single maturity date, amortized cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nuvation Bio's debt securities, available-for-sale, maturity, allocated and single maturity date, amortized cost?
- Nuvation Bio (NUVB) reported debt securities, available-for-sale, maturity, allocated and single maturity date, amortized cost of $365.13M in Q4 2025.
- How has Nuvation Bio's debt securities, available-for-sale, maturity, allocated and single maturity date, amortized cost changed year-over-year?
- Nuvation Bio's debt securities, available-for-sale, maturity, allocated and single maturity date, amortized cost decreased by 21.8% year-over-year, from $466.97M to $365.13M.
- What is the long-term trend for Nuvation Bio's debt securities, available-for-sale, maturity, allocated and single maturity date, amortized cost?
- Over 4 years (2021 to 2025), Nuvation Bio's debt securities, available-for-sale, maturity, allocated and single maturity date, amortized cost has grown at a -12.3% compound annual growth rate (CAGR), from $618.17M to $365.13M.